BCPEMI
AVIR icon

Bain Capital Public Equity Management II’s Atea Pharmaceuticals AVIR Stock Holding History

Bain Capital Public Equity Management II’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-847,208
Closed -$52.3M – 53
2021
Q1 		$52.3M Sell
847,208
-250,000
-23% -$16.9M 2.18% 20
2020
Q4 		$42.3M Buy
+1,097,208
New +$35.4M 2.16% 24

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Bain Capital Public Equity Management II's AVIR Position: Q2 2021 in Review

Bain Capital Public Equity Management II sold out of Atea Pharmaceuticals (AVIR) in Q2 2021, closing a stake of 847,208 shares — an estimated $52.3M sold.

Bain Capital Public Equity Management II first reported a position in AVIR in Q4 2020 and held it in 2 quarters. The position peaked at $52.3M in Q1 2021. 103 funds tracked by Wall St. Rank hold AVIR as of Q2 2021.

  • Bain Capital Public Equity Management II reported no remaining Atea Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Bain Capital Public Equity Management II sold 847,208 Atea Pharmaceuticals shares in Q2 2021, an estimated $52.3M.
  • Bain Capital Public Equity Management II first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Bain Capital Public Equity Management II's Atea Pharmaceuticals position peaked at $52.3M in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2021.

Based on Bain Capital Public Equity Management II's 13F filing for Q2 2021, filed 16 Aug 2021.